Combination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease
Journal Title: Journal of Advances in Medicine and Medical Research - Year 2016, Vol 13, Issue 7
Abstract
Aim: Clinicians are often face the dilemma of choosing more appropriate antithrombotic regimen, since there is no evidence regarding the role of combination of Oral Anticoagulant (OAC) and antiplatelet which played in elderly patients with Atrial Fibrillation (AF) and Ischemic Heart Disease (IHD). We therefore aimed to investigate the effect of combination of OAC and antiplatelet on all-cause mortality in elderly patients with AF and IHD. Study Design: This is a retrospective analytical study. Place and Duration of the Study: The study was conducted in Chinese PLA General Hospital, Beijing, China. Selected patients' data available for the period between 2008 and 2014 were included in this study. Methods: A total of 669 elderly patients with AF and IHD between 2008 and 2014 were included (mean age, 80.8 years; 67.5% men). The endpoint was all-cause mortality. Risk of all-cause death was examined with Kaplan-Meier analysis and adjusted Cox regression models. Results: During a median follow-up of 1.3 years, the mortality rate was 74.3% for patients with antiplatelets, 58.6% for OAC and 42.9% for combination of both, respectively. OAC and /or antiplatelet use were associated with risk of mortality (chi-square=11.03, log rank p = 0.004) using unadjusted Kaplan-Meier analysis. In overall cohort, the adjusted hazard ratios for mortality for combination of OAC and antiplatelet was 0.41 (95% CI 0.19-0.87, p = 0.019) as compared to antiplatelet use, 0.80 (95% CI 0.39-1.64, p = 0.541) as compared to OAC use. In subgroup age ≥ 75 years, the adjusted hazard ratios for mortality were 0.40 (95% CI 0.16-1.02, p = 0.054) for combination of OAC and antiplatelet as compared to antiplatelet use, 0.79 (95% CI 0.31-1.96, p = 0.605) for combination of OAC and antiplatelet as compared to OAC use, and compared to antiplatelet use, the adjusted hazard ratio for mortality were 0.51 (95% CI 0.32-0.81, p = 0.005) for OAC use. Conclusions: Combination of OAC with antiplatelet is associated with reduced all-cause mortality and OAC is better on outcome as compared to antiplatelet agents, but OAC plus antiplatelet is not superior to OAC in elderly patients with AF and IHD and in subgroup aged ≥ 75 years.
Authors and Affiliations
Shijun Li, Li Zhang, Yangyu Wang, Na Li, Hongjie Li
Keywords
Related Articles
- EP ID EP340870
- DOI 10.9734/BJMMR/2016/23637
- Views 69
- Downloads 0
Fibrotic Sarcoidosis Mimics Non-specific Interstitial Pneumonia: A Case Report
Aims: Fibrotic sarcoidosis is not common presentation and it is not easy to diagnose for many differential diagnosis. We herein report an interesting fibrotic sarcoidosis who shows atypical presentation such as progressi...
Bronchial Cytokine Changes Following Bronchial Resection and Reconstruction for Carcinoid Tumor
As bronchial carcinoids are known to be notably rare, adequate histochemical investigations couldn’t have been carried out on these types of tumors hitherto. In this study, we investigated bronchial cytokines in a carcin...
The Effects of Self-care Training on Self-perception in Diabetic Adolescents
Introduction: Some of the problems that diabetic adolescents face are disturbances in mental image, difficulty in communicating with peers, and fear of dependence and lack of self-sufficiency, which cause changes in self...
Peak Expiratory Flow (PEF) in Relation to Selected Anthropometric Parameters in Healthy Adult Males of Kumaun Region of India: A Comparative Study
Background: PEF is a reasonably good measure of ventilatory function. It varies with various anthropometric parameters, geographical location of the subjects as well as various disease processes. Objective: To assess the...
Serum Vitamin D Concentration in Asthmatic Children and Its Association with Recovery Time from an Asthma Exacerbation
Introduction: The relationship of vitamin D and asthma is known but the association between vitamin D and time required to recover from acute asthma exacerbation has not been studied. Aims: To find an association betwee...